Abeona Therapeutics (NASDAQ: ABEO) CCO has shares withheld for taxes on RSU vesting

Rhea-AI Filing Summary

Abeona Therapeutics Chief Commercial Officer Madhav Vasanthavada reported a routine compensation-related share adjustment. On a Form 4 dated for a transaction on June 16, 2026, 222 shares of common stock at $5.67 per share were withheld to satisfy tax obligations upon vesting of restricted stock awards. Following this withholding, he holds 303,229 common shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vasanthavada Madhav

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Other	Common Stock	222	$5.67	$1K

Holdings After Transaction: Common Stock — 303,229 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 222 shares Reference share price: $5.67 per share Shares held after transaction: 303,229 shares

3 metrics

Shares withheld for taxes 222 shares Withheld upon vesting of restricted stock awards on June 16, 2026

Reference share price $5.67 per share Value used for 222 withheld shares

Shares held after transaction 303,229 shares Direct common stock ownership following withholding

Key Terms

restricted stock awards, tax withholding obligations, Form 4

3 terms

restricted stock awards financial

"upon vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

tax withholding obligations financial

"shares withheld to satisfy tax withholding obligations"

Form 4 regulatory

"On a Form 4 dated for a transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vasanthavada Madhav

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		J(1)		222	D	$5.67	303,229	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards.

	/s/ Joseph Vazzano, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for Madhav Vasanthavada?

Abeona reported that Chief Commercial Officer Madhav Vasanthavada had 222 shares of common stock withheld to cover taxes on vested restricted stock awards, a routine compensation-related adjustment rather than an open-market trade.

How many Abeona Therapeutics (ABEO) shares were involved in the latest Form 4?

The Form 4 shows 222 shares of Abeona Therapeutics common stock, valued at $5.67 per share, were withheld to satisfy tax withholding obligations tied to the vesting of restricted stock awards granted as compensation.

Does the Abeona Therapeutics (ABEO) Form 4 reflect a market sale or purchase?

The Form 4 does not reflect a market sale or purchase. It records shares withheld to pay tax obligations on vested restricted stock awards, so no open-market trading decision by the executive is reported in this transaction.

What are Madhav Vasanthavada’s Abeona Therapeutics (ABEO) holdings after this transaction?

After the tax-related withholding of 222 shares, Chief Commercial Officer Madhav Vasanthavada directly holds 303,229 shares of Abeona Therapeutics common stock, according to the Form 4’s post-transaction ownership figure disclosed in the filing.

Why were shares withheld in the Abeona Therapeutics (ABEO) Form 4 filing?

The shares were withheld to satisfy tax withholding obligations arising when restricted stock awards vested. Instead of paying cash for taxes, a portion of the vested shares was retained for tax purposes, which is a standard mechanism in equity compensation plans.